Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Friday 28 January, 2022

Oxford Biomedica PLC

Holdings in Company

RNS Number : 0266A
Oxford Biomedica PLC
28 January 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BDFBVT43

Issuer Name

OXFORD BIOMEDICA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Novo Holdings A/S

City of registered office (if applicable)

Hellerup

Country of registered office (if applicable)

 

Name

Cityofregisteredoffice

Countryofregisteredoffice

NovoNordiskFoundation

Hellerup

Denmark

 

4. Details of the shareholder

Name

Cityof registeredoffice

Countryofregisteredoffice

NovoHoldingsA/S

Hellerup

Denmark

 

5. Date on which the threshold was crossed or reached

01-Jun-2021

6. Date on which Issuer notified

27-Jan-2022

7. Total positions of person(s) subject to the notification obligation


% of votingrights attachedtoshares(total

of 8.A)

% of voting rightsthrough financialinstruments(total

of8.B 1 +8.B2)

Total of bothin % (8.A +8.B)

Total numberof votingrights heldin

issuer

Resultingsituationonthedateonwhich

thresholdwas

 

9.570000

 

0.000000

 

9.570000

 

8253000

crossed or reached





Position of previous notification (if applicable)





 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type ofshares ISINcode(ifpossible)

Number of directvoting rights(DTR5.1)

Number ofindirectvoting

rights(DTR5.2.1)

 

% of direct votingrights(DTR5.1)

% of indirectvoting rights(DTR5.2.1)

GB00BDFBVT43

8253000

0

9.570000

0.000000

 

SubTotal 8.A

8253000

9.570000%

 

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 

Typeoffinancialinstrument

 

Expirationdate

 

Exercise/conversionperiod

Number of voting rights thatmay be acquired if theinstrument isexercised/converted

% ofvotingrights

SubTotal 8.B1




 

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type offinancialinstrument

Expirationdate

Exercise/conversionperiod

Physical or cashsettlement

Number ofvotingrights

% ofvotingrights

SubTotal 8.B2




 

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

The position of Novo Holdings A/S in its previous TR-1 notification was 10.1%. This notification obligation has arisen as a result of issuances of shares by the issuer (and not a disposal of shares by Novo Holdings A/S) and is based upon the latest total voting rights announcement of the issuer dated 4 January 2022.

The qualifying instruments are held by Novo Holdings A/S, the holding company in the Novo Group. Novo Holdings A/S is wholly owned by the Novo Nordisk Foundation.

12. Date of Completion

27-Jan-2022

13. Place Of Completion

London, United Kingdom

Contact name:

Natalie Walter

Contact telephone number:

01865 783000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEADFPALPAEFA

a d v e r t i s e m e n t